Goldman Sachs lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $49 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)
- Mineralys Therapeutics initiated with a Buy at TD Cowen
- Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board
- Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer
- Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety